Risk and reward. It is a balance that has to be achieved in any business endeavor and is of utmost importance for pharmaceutical and biopharmaceutical companies managing their growth and manufacturing in emerging markets. Emerging markets are a crucial part of pharmaceutical companies’ growth strategies, but in serving those markets, pharmaceutical and biopharmaceutical manufacturers must align that strategy with partners that can facilitate access to local markets, manage complex supply chains, meet global and national regulatory standards for quality, and secure production for local as well as established markets in North America and Western Europe.
Pharmaceutical Technology will examine these issue in greater depth in an educational live webcast, Risk-Mitigation Strategies for API Manufacturing in Emerging Markets, on Wednesday June 19 11:00 AM to 12:00 PM EST. This 60-minute webcast will provide insight and case-study analysis on the approaches taken by pharmaceutical companies to build their manufacturing networks in select emerging markets while mitigating risk in supplier selection and qualification to ensure reliable and consistent product supply.
Panelists for the webcast include Thomas Niemeyer, Global External Supply Lead, Chemical Research & Development, Pfizer; Andy Wong, Principal, IMS Consulting Group; and Thomas Speace, President, Neuland Laboratories. The panelists will share insight into the opportunities in emerging markets; how to apply risk-mitigation strategies for supplier selection and qualification; how to manage supply chains for intermediates and APIs; and elucidate the regulatory and unique national requirements in emerging markets for pharmaceutical manufacturing.
Audience members will be able to ask the panelists questions for additional insight during the live webcast on Wednesday June 19 from 11:00 AM to 12:00 PM EST. Additional information and how to register for the live webcast and on-demand viewing may be found here.